Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

References

• SlamonDJ, Leyland-JonesB, ShakS, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. doi:10.1056/NEJM20010315344110111248153
   PubMed Web of Science ®Google Scholar
• DelucheE, AntoineA, BachelotT, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer. 2020;129:60–70. doi:10.1016/j.ejca.2020.01.01632135312
   PubMed Web of Science ®Google Scholar
• MurphyCG, MorrisPG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs. 2012;23:765–776. doi:10.1097/CAD.0b013e328352d29222824822
   PubMed Web of Science ®Google Scholar
• GleesonJP, KeeganNM, MorrisPG. Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer. Expert Opin Biol Ther. 2018;18:251–262. doi:10.1080/14712598.2018.141013229183167
   PubMed Web of Science ®Google Scholar
• SwainSM, BaselgaJ, KimSB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2014. doi:10.1056/NEJMoa1413513
   Web of Science ®Google Scholar
• VermaS, MilesD, GianniL, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791. doi:10.1056/NEJMoa120912423020162
   PubMed Web of Science ®Google Scholar
• GeyerCE, ForsterJ, LindquistD, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743. doi:10.1056/NEJMoa06432017192538
   PubMed Web of Science ®Google Scholar
• CameronD, CaseyM, OlivaC, NewstatB, ImwalleB, GeyerCE. Lapatinib plus capecitabine in women with HER‐2–positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15:924–934. doi:10.1634/theoncologist.2009-018120736298
   PubMed Web of Science ®Google Scholar
• SauraC, OliveiraM, FengY-H, et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial. J Clin Oncol. 2019;37:1002. doi:10.1200/jco.2019.37.15_suppl.1002
   Web of Science ®Google Scholar
• MurthyRK, LoiS, OkinesA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;597–609. doi:10.1056/NEJMoa1914609.31825569
   PubMed Web of Science ®Google Scholar
• RugoHS, ImS-A, WrightGLS, et al. SOPHIA primary analysis: a phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). J Clin Oncol. 2019;37:1000. doi:10.1200/jco.2019.37.15_suppl.1000
   Web of Science ®Google Scholar
• ModiS, SauraC, YamashitaT, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–621. doi:10.1056/NEJMoa191451031825192
   PubMed Web of Science ®Google Scholar
• XuZ, GuoD, JiangZ, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682. doi:10.1016/j.ejmech.2019.11168231563805
   PubMed Web of Science ®Google Scholar
• TamuraK, TsurutaniJ, TakahashiS, et al. Trastuzumab deruxtecan (DS-8201a)in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20:816–826. doi:10.1016/S1470-2045(19)30097-X31047803
   PubMed Web of Science ®Google Scholar
• AndrikopoulouA, ZografosE, LiontosM, KoutsoukosK, DimopoulosMA, ZagouriF. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer. Clin Breast Cancer. 2020. doi:10.1016/j.clbc.2020.08.006
   PubMed Web of Science ®Google Scholar
• García-AlonsoS, OcañaA, PandiellaA. Resistance to antibody–drug conjugates. Cancer Res. 2018;78:2159–2165. doi:10.1158/0008-5472.CAN-17-367129653942
   PubMed Web of Science ®Google Scholar
• Ríos-LuciC, García-AlonsoS, Díaz-RodríguezE, et al. Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res. 2017;77:4639–4651. doi:10.1158/0008-5472.CAN-16-312728687619
   PubMed Web of Science ®Google Scholar
• BanerjiU, van HerpenCML, SauraC, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1124–1135. doi:10.1016/S1470-2045(19)30328-631257177
   PubMed Web of Science ®Google Scholar
• DoiT, ShitaraK, NaitoY, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512–1522. doi:10.1016/S1470-2045(17)30604-629037983
   PubMed Web of Science ®Google Scholar
• ModiS, ParkH, MurthyRK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38:1887–1896. doi:10.1200/JCO.19.0231832058843
   PubMed Web of Science ®Google Scholar
• YazakiS, HashimotoJ, OgitaS, NakanoE, YamauchiT. Lower response to T-DM1 in metastatic breast cancer patients with HER2 IHC score of 2 and FISH positive compared with IHC score of 3. Ann Oncol. 2017;28:v102–v103. doi:10.1093/annonc/mdx365.071
   Google Scholar
• FehrenbacherL, CecchiniRS, GeyerCE, et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J Clin Oncol. 2020;38:444–453. doi:10.1200/JCO.19.0145531821109
   PubMed Web of Science ®Google Scholar
• ShitaraK, BangY-J, IwasaS, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–2430. doi:10.1056/nejmoa200441332469182
   PubMed Web of Science ®Google Scholar
• TsurutaniJ, IwataH, KropI, et al. Targeting her2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors. Cancer Discov. 2020;10:688–701. doi:10.1158/2159-8290.CD-19-101432213540
   PubMed Web of Science ®Google Scholar
• KropIE, KimSB, MartinAG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743–754. doi:10.1016/S1470-2045(17)30313-328526538
   PubMed Web of Science ®Google Scholar
• BardiaA, MayerIA, VahdatLT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–751. doi:10.1056/NEJMoa181421330786188
   PubMed Web of Science ®Google Scholar
• PowellC, CamidgeD, GemmaA, et al. Abstract P6-17-06: characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomera. Cancer Res. 2019. doi:10.1158/1538-7445.sabcs18-p6-17-06
   Web of Science ®Google Scholar
• KuboK, AzumaA, KanazawaM, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51:260–277. doi:10.1016/j.resinv.2013.09.001
   PubMedGoogle Scholar
• EnomotoY, InuiN, ImokawaS, et al. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Cancer Chemother Pharmacol. 2015;76:499–505. doi:10.1007/s00280-015-2816-626134440
   PubMed Web of Science ®Google Scholar
• Von MinckwitzG, HuangCS, ManoMS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628. doi:10.1056/NEJMoa181401730516102
   PubMed Web of Science ®Google Scholar
• IwataTN, IshiiC, IshidaS, OgitaniY, WadaT, AgatsumaT. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17:1494–1503. doi:10.1158/1535-7163.MCT-17-074929703841
   PubMed Web of Science ®Google Scholar